| 臺大學術典藏 |
2022-06-10T06:10:53Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-06-10T06:10:52Z |
Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma
|
Chen C.-T.; Liu T.-H.; Shao Y.-Y.; Liu K.-L.; Liang P.-C.; ZHONG-ZHE LIN |
| 臺大學術典藏 |
2022-05-12T01:36:49Z |
Computed tomography-based sarcopenia in patients receiving peritoneal dialysis: Correlation with lean soft tissue and survival
|
Wu C.H.; CHIA-TER CHAO; Liang P.C.; Shih T.T.F.; Huang J.W. |
| 臺大學術典藏 |
2022-04-07T01:43:07Z |
Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma
|
Chen C.-T.; TSUNG-HAO LIU; Shao Y.-Y.; Liu K.-L.; Liang P.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-03-08T03:44:04Z |
Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan
|
Chang M.-C.; Wu C.-H.; SHIH-HUNG YANG; Liang P.-C.; Chen B.-B.; Jan I.-S.; Chang Y.-T.; Jeng Y.-M. |
| 臺大學術典藏 |
2022-03-04T06:55:01Z |
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
|
SIH-HAN LIAO; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; Chen C.-H.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:41Z |
Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma.
|
Liang J.D.; Yang P.M.; Huang G.T.; Lee H.S.; CHIEN-HUNG CHEN; Liang P.C.; Sheu J.C.; Chen D.S. |
| 臺大學術典藏 |
2022-02-23T02:12:28Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai W.-L.; Liang P.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:27Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; CHIEN-HUNG CHEN; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment
|
Chang P.-Y.; Huang C.-C.; Hung C.-H.; Yu C.-Y.; Wu D.-K.; Hwang J.-I.; Liang P.-C.; Wu R.-H.; Tsai W.-L.; Lin Y.-J.; Liu Y.-S.; Liang H.-L.; Lee R.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-23T02:12:23Z |
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
|
Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; CHIEN-HUNG CHEN; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:20Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-22T05:34:36Z |
Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma.
|
Liang J.D.; Yang P.M.; Huang G.T.; Lee H.S.; CHIEN-HUNG CHEN; Liang P.C.; Sheu J.C.; Chen D.S. |
| 臺大學術典藏 |
2022-02-22T05:34:20Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai W.-L.; Liang P.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:18Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; CHIEN-HUNG CHEN; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:14Z |
Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment
|
Chang P.-Y.; Huang C.-C.; Hung C.-H.; Yu C.-Y.; Wu D.-K.; Hwang J.-I.; Liang P.-C.; Wu R.-H.; Tsai W.-L.; Lin Y.-J.; Liu Y.-S.; Liang H.-L.; Lee R.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:13Z |
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
|
Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; CHIEN-HUNG CHEN; Kao J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-16T03:16:57Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; YU-YUN SHAO; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-16T03:16:56Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; YU-YUN SHAO; Hsu C.; Hsu C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-16T03:16:55Z |
Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma
|
Chen C.-T.; Liu T.-H.; YU-YUN SHAO; Liu K.-L.; Liang P.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-16T03:00:55Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao, Yu-Yun; Wang, Shen-Yung; Lin, Shi-Ming; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; JA-DER LIANG |
| 臺大學術典藏 |
2022-02-07T03:29:04Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-07T03:29:03Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; Shao Y.-Y.; Hsu C.; CHIH-HUNG HSU; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-01-25T05:10:42Z |
Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis
|
Chang M.-C.; Chang Y.-T.; Su T.-C.; Yang W.-S.; CHI-LING CHEN; Tien Y.-W.; Liang P.-C.; Wei S.-C.; Wong J.-M. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:34Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; Shao Y.-Y.; CHIUN HSU; Hsieh C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-01-17T08:00:26Z |
Metallic ureteral stents in malignant ureteral obstruction: Clinical factors predicting stent failure
|
Chow P.-M.; Hsu J.-S.; Huang C.-Y.; Wang S.-M.; YUAN-JU LEE; Huang K.-H.; Yu H.-J.; Pu Y.-S.; Liang P.-C. |
| 臺大學術典藏 |
2022-01-03T05:51:03Z |
Simultaneous Endovascular Treatment of a Ureteroiliac Fistula and Common Iliac Artery Occlusion
|
Wu I.-H.; SHIH-CHIEH CHUEH; Liang P.-C. |
| 臺大學術典藏 |
2022 |
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Cheng A.-L.; CHIH-HUNG HSU; Hsu C.; Lin Z.-Z.; Lu L.-C.; Chen B.-B.; Liang P.-C.; Shih T.T.-F.; Liu T.-H.; Shen Y.-C. |
| 臺大學術典藏 |
2021-10-14T02:45:53Z |
Metallic ureteral stents in malignant ureteral obstruction: Clinical factors predicting stent failure
|
Chow P.-M.; Hsu J.-S.; CHAO-YUAN HUANG; Wang S.-M.; Lee Y.-J.; Huang K.-H.; Yu H.-J.; Pu Y.-S.; Liang P.-C. |
| 臺大學術典藏 |
2021-09-14T04:36:06Z |
Effects of high-flow nasal oxygen during prolonged deep sedation on postprocedural atelectasis: A randomised controlled trial
|
CHUNG-CHIH SHIH; Liang P.-C.; Chuang Y.-H.; Huang Y.-J.; Lin P.-J.; Wu C.-Y. |
| 臺大學術典藏 |
2021-09-04T06:11:43Z |
Hepatic necro-inflammation and elevated liver enzymes: Evaluation with MRI perfusion imaging with gadoxetic acid in chronic hepatitis patients
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; JIA-HORNG KAO; Lee H.-S.; Liang P.-C.; Wei S.-Y.; Hwang R.-M.; Shih T.T.-F. |
| 臺大學術典藏 |
2021-09-04T06:11:42Z |
Vascular and hepatic enhancements at MR imaging: Comparison of Gd-EOB-DTPA and Gd-DTPA in the same subjects
|
Lin Y.-H.; Hwang R.-M.; Chen B.-B.; Hsu C.-Y.; Yu C.-W.; JIA-HORNG KAO; Lee H.-S.; Liang P.-C.; Wei S.-Y.; Shih T.T.F. |
| 臺大學術典藏 |
2021-09-04T05:16:56Z |
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
|
Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; Chen C.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:22Z |
Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma
|
Wu C.-H.; Liang P.-C.; Su T.-H.; Lin M.-C.; Chang Y.-H.; Shih T.T.-F.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-01T01:54:22Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Shao Y.-Y.; Lin Z.-Z.; Liang P.-C.; Tien Y.-W.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:45Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG; Lin Z.-Z. |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.; ANN-LII CHENG; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-20T08:19:30Z |
Computed tomography-based sarcopenia in patients receiving peritoneal dialysis: Correlation with lean soft tissue and survival
|
Wu C.H.; CHIA-TER CHAO; Liang P.C.; Shih T.T.F.; Huang J.W. |
| 臺大學術典藏 |
2021-08-12T04:01:26Z |
Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan
|
Chang M.-C.; Wu C.-H.; YANG SHIH-HUNG; Liang P.-C.; Chen B.-B.; Jan I.-S.; Chang Y.-T.; Jeng Y.-M. |
| 臺大學術典藏 |
2021-08-11T03:46:51Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Shao Y.-Y.; ZHONG-ZHE LIN; Liang P.-C.; Tien Y.-W.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:43Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN |
